| Overview |
| bs-8400R-PE |
| BTBD17 Polyclonal Antibody, PE Conjugated |
| WB |
| Human, Mouse, Rat |
| Dog, Sheep |
| Specifications |
| PE |
| Rabbit |
| KLH conjugated synthetic peptide derived from human BTBD17 |
| 101-200/478 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 388419 |
| A6NE02 |
| Secreted |
| BTB/POZ domain-containing protein 17; btbd17; BTBDH_HUMAN; Galectin-3-binding protein-like. |
| The BTB (broad-complex, Tramtrack and Bric a brac) domain, also known as the POZ (Poxvirus and zinc finger) domain, is an N-terminal homodimerization domain that contains multiple copies of kelch repeats and/or C2H2-type zinc fingers. Proteins that contain BTB domains are thought to be involved in transcriptional regulation via control of chromatin structure and function. BTBD17 (BTB/POZ domain-containing protein 17), also known as BTBD17A, galectin-3-binding protein-like or LGALS3BPL, is a 478 amino acid protein that contains one BTB (POZ) domain and a BACK (BTB/Kelch associated) domain. The gene encoding BTBD17 maps to human chromosome 17, which comprises over 2.5% of the human genome and encodes over 1,200 genes. Two key tumor suppressor genes are associated with chromosome 17, namely, p53 and BRCA1. Malfunction or loss of p53 expression is associated with malignant cell growth and Li-Fraumeni syndrome. |
| Application Dilution |
| WB |
1:300-5000 |
Powered by Bioz